Top Page
Cantargia AB
(Frankfurt:CANTA)
Cantargia AB (CANTA) vs. iShares MSCI Sweden ETF (EWD)
Cantargia AB Business Overview & Revenue Model
Cantargia AB Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -3.45M | -3.69M | -3.45M | -3.25M | EBIT |
| -168.58M | -290.02M | -381.55M | -370.27M | -173.94M | EBITDA |
| -165.05M | -284.31M | -375.96M | -363.06M | -169.84M | Net Income Common Stockholders |
| -161.65M | -280.03M | -362.08M | -366.51M | -173.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 33.04M | 194.75M | 426.67M | 559.39M | 903.37M | Total Assets |
| 170.43M | 223.71M | 474.80M | 600.24M | 925.51M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -33.04M | -139.75M | -189.57M | -247.32M | -693.35M | Total Liabilities |
| 54.12M | 54.97M | 85.11M | 67.50M | 33.58M | Stockholders Equity |
| 116.30M | 168.74M | 389.68M | 532.75M | 891.93M |
| Cash Flow | Free Cash Flow | |||
| -162.75M | -286.66M | -366.00M | -346.83M | -165.39M | Operating Cash Flow |
| -162.75M | -286.66M | -358.92M | -346.44M | -156.39M | Investing Cash Flow |
| 55.00M | 182.09M | 67.88M | -102.43M | -109.00M | Financing Cash Flow |
| -1.07M | 54.68M | 223.93M | 3.00K | 918.51M |
Cantargia AB Technical Analysis
Cantargia AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
48 Neutral | kr379.37M | ― | -47.73% | ― | 45.52% | 93.35% | |
44 Neutral | €267.41M | ― | -18.79% | ― | ― | 21.85% | |
40 Underperform | kr321.97M | ― | ― | 1.72% | 32.54% | ||
36 Underperform | €185.74M | ― | -54.29% | ― | -100.00% | -17.35% | |
32 Underperform | €375.12M | ― | -205.65% | ― | ― | 24.25% | |
31 Underperform | kr289.38M | ― | -167.55% | ― | ― | 46.67% |
Cantargia AB Corporate Events
Cantargia AB has announced new preclinical data demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression, potentially overcoming resistance to immune therapy in cancer treatment. The findings, published in Cancer Discovery, show that nadunolimab can reduce immunosuppressive cells and enhance the efficacy of cancer vaccines, highlighting its potential to improve immunotherapy outcomes, particularly in pancreatic and non-small cell lung cancer patients.
Cantargia AB has announced preclinical data published in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression. The study, conducted by Professor Douglas Hanahan’s team, shows that blocking IL1RAP can overcome resistance to immune therapy in cervical cancer models, suggesting broader potential for nadunolimab in cancer treatment. Clinical data supports these findings, showing a significant decrease in circulating neutrophils in patients treated with nadunolimab, underscoring its potential to improve immunotherapy outcomes.
Cantargia AB has announced the publication of preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression in cancer. The study, led by Professor Douglas Hanahan, showed that blocking IL1RAP with a nadunolimab surrogate antibody can overcome resistance to immune therapy in a cervical cancer model. These findings are supported by clinical data showing nadunolimab’s potential to reduce immunosuppressive myeloid cells, suggesting its broader potential in cancer treatment. The research highlights the role of IL-1 family cytokines in systemic immunosuppression and the potential of nadunolimab to enhance the efficacy of cancer vaccines and improve immunotherapy outcomes.
Cantargia AB has published preclinical data in Cancer Discovery demonstrating that targeting IL1RAP with nadunolimab can effectively counteract tumor-induced systemic immune suppression by blocking immune suppressive myeloid cells. The findings, supported by clinical data, highlight nadunolimab’s potential to enhance cancer treatment by reducing immunosuppressive neutrophils and improving the efficacy of cancer vaccines. These results suggest significant implications for improving immunotherapy outcomes, particularly in cancers like pancreatic and non-small cell lung cancer.
Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression, potentially enhancing cancer treatment. The findings, supported by clinical data, show that nadunolimab can reduce immunosuppressive cells and improve the efficacy of cancer vaccines, suggesting significant potential for improving immunotherapy outcomes in cancer treatment.
Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can counteract tumor-driven systemic immunosuppression, which is a significant barrier to effective cancer immunotherapy. The findings, supported by clinical data, show that nadunolimab can reduce immunosuppressive cells and enhance the efficacy of cancer vaccines, suggesting a promising potential for improving cancer treatment outcomes.
Cantargia AB announced preclinical data showing that targeting IL1RAP can effectively counteract tumor-induced systemic immune suppression, potentially enhancing cancer treatment outcomes. These findings, published in Cancer Discovery, highlight nadunolimab’s ability to reduce immunosuppressive myeloid cells, suggesting significant implications for improving immunotherapy responses in cancer patients.
Cantargia AB has published preclinical data demonstrating that targeting IL1RAP with nadunolimab can effectively counteract tumor-induced systemic immune suppression in cancer. The findings, published in Cancer Discovery, show that blocking IL1RAP can overcome resistance to immune therapy, particularly in cervical cancer models, and enhance the efficacy of cancer vaccines. Clinical data further supports nadunolimab’s potential to improve immunotherapy outcomes, highlighting its significance in cancer treatment and its potential impact on patient prognosis.
Cantargia AB announced new preclinical data published in Cancer Discovery, demonstrating that targeting IL1RAP with nadunolimab can counteract tumor-driven systemic immunosuppression. The findings suggest that nadunolimab could enhance the efficacy of cancer vaccines and improve outcomes in cancer treatment by reducing immunosuppressive cells and enhancing T cell responses. Clinical data supports these findings, showing a significant decrease in neutrophils and improved prognostic indicators in patients treated with nadunolimab, highlighting its potential to improve immunotherapy outcomes.
Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP with nadunolimab can counteract tumor-driven systemic immunosuppression, potentially enhancing the effectiveness of cancer treatment. The findings, supported by clinical data, suggest that nadunolimab could improve outcomes in cancer therapies by reducing immunosuppressive cells and enhancing anti-tumor immune responses, thus positioning Cantargia as a significant player in advancing cancer immunotherapy.
Cantargia AB has published preclinical data in Cancer Discovery, showcasing the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The findings indicate that blocking IL1RAP can overcome resistance to immune therapy, with clinical data supporting the reduction of immunosuppressive cells and improved outcomes in cancer treatment. This development could enhance Cantargia’s positioning in the oncology sector by offering a promising approach to improving immunotherapy outcomes, potentially benefiting stakeholders and patients alike.
Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The findings, supported by clinical data, suggest that nadunolimab can enhance the efficacy of cancer vaccines and improve immunotherapy outcomes by reducing immunosuppressive cells and boosting anti-tumor immunity. This development could significantly impact cancer treatment, offering new avenues for overcoming resistance to immune therapies and improving patient prognoses.
Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The study, conducted by Professor Douglas Hanahan’s team, demonstrated that blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model, suggesting broader implications for cancer treatment. Clinical data supports these findings, showing nadunolimab’s ability to reduce immunosuppressive cells and improve immunotherapy outcomes, potentially enhancing Cantargia’s position in the oncology market.
Cantargia AB has announced new preclinical data published in Cancer Discovery, demonstrating the potential of their antibody nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. This research, led by Professor Douglas Hanahan, shows that blocking IL1RAP can overcome resistance to immune therapy in cancer models, with clinical data supporting these findings by showing a reduction in immunosuppressive cells in patients treated with nadunolimab. These insights suggest that nadunolimab could significantly enhance cancer treatment efficacy, particularly in overcoming resistance to existing therapies, thus potentially improving outcomes for patients and strengthening Cantargia’s position in the oncology field.
Cantargia AB announced the publication of preclinical data in Cancer Discovery, highlighting nadunolimab’s potential to counteract tumor-driven systemic immunosuppression. The study, conducted by Professor Douglas Hanahan’s team, shows that targeting IL1RAP can inhibit tumor-induced immune suppression, with clinical data supporting these findings. The research suggests that nadunolimab could enhance cancer treatment by overcoming resistance to immune therapies, potentially improving outcomes for patients with high neutrophil counts.
Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The study, conducted by Professor Douglas Hanahan’s research group, demonstrates that blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model. The findings are supported by clinical data showing nadunolimab’s ability to reduce immunosuppressive cells, suggesting significant potential in improving cancer treatment outcomes.